Smith & Nephew
Smith & Nephew is an industry leader in each of our three main Global Business Units - Orthopaedic Reconstruction and Trauma, Endoscopy and Advanced Wound Management. These businesses jointly offer over 1,000 product ranges.
Our global infrastructure continues to expand each year. We currently operate in 32 countries and generate annual sales of $3.4 billion. Substantial investment in our products and intensive research and development means that we are always ahead. Figures from last year show that we stand at number one as the leading company in Arthroscopy. We are the second largest organisation in Advanced Wound Management and number three in Trauma and Clinical Therapies. We are also positioned at number four in reconstruction.
Smith & Nephew has a track record of bringing innovative new products to market that provide better clinical outcomes for patients and save costs for healthcare providers. This is the primary focus of our fourth business unit, Biologics.
| Type | Public |
| HQ | London, GB |
| Founded | 1856 |
| Size (employees) | 15,000 (est) |
| Website | global.smith-nephew.com |
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at Smith & Nephew
Olivier Bohuon
Graham Baker
John W. Campo
Helen Maye
Philippe Mazas
Smith & Nephew Office Locations
Smith & Nephew Financials and Metrics
Smith & Nephew Revenue
| GBP | |
|---|---|
Revenue (FY, 2017) | 3.5b |
Gross profit (FY, 2017) | 2.6b |
Gross profit margin (FY, 2017), % | 73.8% |
Net income (FY, 2017) | 556.8m |
EBITDA (FY, 2017) | 993.8m |
EBIT (FY, 2017) | 678.0m |
Market capitalization (14-Dec-2018) | 32.0m |
Closing stock price (14-Dec-2018) | 0.4 |
Cash (31-Dec-2017) | 122.7m |
EV | (71.0m) |
- Source: Company Filings
| GBP | FY, 1996 | FY, 1997 | FY, 1998 | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.1b | 1.0b | 1.1b | 1.1b | 1.1b | 1.1b | 1.1b | 1.2b | 1.2b | 1.4b | 1.4b | 2.0b | 2.9b | 3.2b | 3.6b | 3.4b | 3.5b |
Revenue growth, % | 11% | 0% | 13% | ||||||||||||||
Cost of goods sold | 472.6m | 446.1m | 453.3m | 479.6m | 456.8m | 350.2m | 329.9m | 345.1m | 334.8m | 361.0m | 1.1b | 600.7m | 724.8m | 797.5m | 883.4m | 923.3m | 905.9m |
Gross profit | 596.6m | 602.0m | 600.1m | 640.3m | 677.9m | 731.5m | 780.0m | 833.8m | 913.7m | 1.0b | 292.0m | 1.4b | 2.1b | 2.4b | 2.7b | 2.5b | 2.6b |
- Source: Company Filings
| GBP | FY, 1996 | FY, 1997 | FY, 1998 | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 80.5m | 57.1m | 49.9m | 100.5m | 24.6m | 30.0m | 22.5m | 26.0m | 32.6m | 88.0m | 177.0m | 102.7m | 90.3m | 63.8m | 92.8m | 72.6m | 122.7m |
Accounts Receivable | 218.7m | 219.9m | 233.1m | 241.8m | 246.2m | 224.4m | 222.6m | 246.0m | 273.5m | 323.0m | 322.0m | 468.3m | 616.1m | 664.3m | 751.3m | 717.2m | 766.6m |
Inventories | 229.8m | 225.7m | 242.4m | 237.6m | 228.2m | 232.2m | 229.5m | 230.6m | 284.9m | 355.0m | 316.0m | 504.0m | 662.8m | 810.5m | 940.6m | 903.0m | 946.6m |
Current Assets | 564.5m | 561.3m | 570.9m | 619.2m | 530.6m | 525.4m | 532.7m | 591.1m | 679.3m | 937.0m | 840.0m | 1.2b | 1.5b | 1.7b | 1.9b | 1.8b | 2.0b |
| GBP | FY, 1996 | FY, 1997 | FY, 1998 | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 120.7m | 113.7m | 93.7m | 104.8m | 205.2m | 129.6m | 112.1m | 148.1m | 125.2m | 170.0m | 201.0m | 191.0m | 366.3m | 343.8m | 316.9m | 569.1m | 556.8m |
Cash From Operating Activities | 189.3m | 181.7m | 161.9m | 198.1m | 204.0m | 191.9m | 209.3m | 214.5m | 226.6m | 147.0m | 190.0m | 264.7m | 571.3m | 468.7m | 796.1m | 616.3m | 791.2m |
Dividends Paid | 66.5m | 69.0m | 69.2m | 72.5m | 456.9m | 42.9m | 44.6m | 46.1m | 47.8m | 50.0m | 49.0m | 62.8m | 157.5m | 164.0m | 202.5m | 195.3m | |
Cash From Financing Activities | 40.4m | (19.7m) | 158.7m | 17.8m | 94.8m | (93.1m) | (16.9m) | (22.0m) | (196.0m) | 209.7m | (328.1m) | 691.8m | (431.3m) | (384.0m) | (315.0m) |
| GBP | Y, 2017 |
|---|---|
EV/EBITDA | -0.1 x |
EV/EBIT | -0.1 x |
EV/CFO | -0.1 x |
Revenue/Employee | 228.4k |
Financial Leverage | 1.7 x |
Smith & Nephew Operating Metrics
| FY, 2016 | |
|---|---|
Training Provided, no. of people | 90 k |
Smith & Nephew Revenue Breakdown
Smith & Nephew revenue breakdown by business segment: 12.9% from Sports Medicine Joint Repair , 13.9% from Arthroscopic Enabling Technologies , 9.9% from Trauma & Extremities, 19.8% from Knee Implants, 12.9% from Hip Implants, 14.9% from Advanced Wound Care, 6.9% from Advanced Wound Bioactives and 8.9% from Other
Smith & Nephew Online and Social Media Presence
3.71k Twitter followers
Smith & Nephew has 3.71k Twitter Followers. The number of followers has increased 1.8% month over month and increased 8.1% quarter over quarter
Smith & Nephew News and Updates
Sterile X-Ray Detectable Lap Sponges Market Poised to Achieve Significant Growth in the Years to Come 2026 By Top Players Medline Industries, Inc., Medtronic, Mölnlycke Health Care AB., Baxter., 3M, Smith & Nephew, Johnson & Johnson Services, Inc.
Negative Pressure Wound Therapy Devices Industry Key Manufacturers Analysis Acelity, Molnlycke Health Care, Smith & Nephew, Cardinal Health
Cardiothoracic Minimally Invasive Surgical Instruments Market Analysis 2018: Medtronic, Aesculap, Smith & Nephew, Ethicon, Conmed Corporation, Zimmer Holdings, KARL STORZ, Genesee BioMedical, MI, Stryker Corporation
Minimally Invasive Surgery Devices Market: In-Depth Industry Analysis On Size, Trend, Segments And Exclusive Manufacturers (Johnson & Johnson, B. Braun Melsungen, Smith & Nephew, Zimmer Biomet) |Global Forecast To 2023
Small Bone and Joint Orthopedic Devices 2018 Global Market Key Players – Acumed, Arthrex, DePuy Synthes, Smith & Nephew, Stryker – Analysis and Forecast to 2021
Waterproof Surgical Tapes 2018 Global Market Key Players – 3M, Johnson & Johnson, Smith & Nephew, Medtronic, DYNAREX – Analysis and Forecast to 2025
Smith & Nephew Company Life and Culture
Smith & Nephew Frequently Asked Questions
When was Smith & Nephew founded?
Smith & Nephew was founded in 1856.
Who are Smith & Nephew key executives?
Smith & Nephew's key executives are Olivier Bohuon, Graham Baker and John W. Campo.
How many employees does Smith & Nephew have?
Smith & Nephew has 15,000 employees.
What is Smith & Nephew revenue?
Latest Smith & Nephew annual revenue is £3.5 b.
What is Smith & Nephew revenue per employee?
Latest Smith & Nephew revenue per employee is £230.6 k.
Who are Smith & Nephew competitors?
Competitors of Smith & Nephew include Stryker, Integer Holdings and Advanced Biomedical Technologies.
Where is Smith & Nephew headquarters?
Smith & Nephew headquarters is located at 15 Adam Street, London.
Where are Smith & Nephew offices?
Smith & Nephew has offices in London, São Paulo, Memphis, Fort Worth and in 4 other locations.
How many offices does Smith & Nephew have?
Smith & Nephew has 8 offices.